GT
AGIO icon

Glenmede Trust’s Agios Pharmaceuticals AGIO Stock Holding History

Glenmede Trust’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-275
Closed -$9K – 1214
2020
Q3 		$9K Buy
275
+46
+20% +$2.02K ﹤0.01% 1903
2020
Q2 		$12K Sell
229
-147
-39% -$6.81K ﹤0.01% 1786
2020
Q1 		$17K Hold
376
– – ﹤0.01% 2167
2019
Q4 		$17K Buy
376
+349
+1,293% +$13.2K ﹤0.01% 2167
2019
Q3 		$0 Buy
+27
New +$1.12K ﹤0.01% 3000
2019
Q1 		– Sell
-245
Closed -$11K – 3046
2018
Q4 		$11K Buy
+245
New +$15.1K ﹤0.01% 2221
2018
Q3 		– Sell
-780
Closed -$66K – 1433
2018
Q2 		$66K Buy
+780
New +$68K ﹤0.01% 1363
2015
Q2 		– Sell
-763
Closed -$71K – 2675
2015
Q1 		$71K Buy
+763
New +$85.5K ﹤0.01% 1567

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Glenmede Trust's AGIO Position: Q4 2020 in Review

Glenmede Trust sold out of Agios Pharmaceuticals (AGIO) in Q4 2020, closing a stake of 275 shares — an estimated $9K sold.

Glenmede Trust first reported a position in AGIO in Q1 2015 and held it in 8 quarters. The position peaked at $71K in Q1 2015. 201 funds tracked by Wall St. Rank hold AGIO as of Q4 2020.

  • Glenmede Trust reported no remaining Agios Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 275 Agios Pharmaceuticals shares in Q4 2020, an estimated $9K.
  • Glenmede Trust first reported a position in Agios Pharmaceuticals in Q1 2015 and held it in 8 quarters.
  • Glenmede Trust's Agios Pharmaceuticals position peaked at $71K in Q1 2015.
  • 201 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.